Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
Date:3/10/2012

in royalty revenues was in line with our expectations and results from a decline in sales of Thalomid® in the United States.  We will continue to carefully monitor and control expenses and deploy capital in strategic ways."  Further up-to-date information regarding the Company, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, can be found on our web site at www.entremed.com.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently completing a multi-center Phase 2 study in ovarian cancer and completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expect
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
2. EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results
3. EntreMed Reports Receipt of Third Quarter Royalty Payment
4. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
5. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
6. EntreMed to Present at the New York Society of Security Analysts Industry Conference
7. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
8. EntreMed Reports Third Quarter 2008 Financial Results
9. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
10. EntreMed to Present at BioPartnering Europe Conference
11. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Having judged last years a success, the ... opened the second annual Wisconsin Governor's Business Plan ... ,Interested businesses will submit 250-word business proposals within one ... and business services. The proposals will be accepted until ...
... open Thursday , Madison, Wis. The UW-Madison ... advances in nanotechnology, run by the university and Milwaukees ... December 16 during a campus open house, with parking in ... as the manufacture of tiny robots, has led to many ...
... Gateway Technical College has almost finished ... Advanced Career Education Program , and already it has gained ... its ideas. , ,The college receieved a grant on Tuesday ... part by the success of its partnership program. The funds ...
Cached Biology Technology:Governors business-plan competition starts another round 2Governors business-plan competition starts another round 3Tech Digest: Nanotechnology, GE Healthcare, NovaMed, PhysioGenix 2Gateway Technical College pilots IBM training program 2
(Date:7/10/2014)... business incubator, received a $1.4 million federal grant to ... staunch bleeding during brain surgery. , Surgeons can spray ... bio-polymer solutions in the gel will cohere and control ... The gel can shorten an intracranial surgery by 30- ... the patient,s skull to be open and less anesthesia, ...
(Date:7/10/2014)... today that Courtney Aldrich, Ph.D., will head the ... as editor-in-chief. With the first issue slated for ... meet a growing demand for a place to ... vision is to develop a journal focused on ... science that advances the field and lays the ...
(Date:7/10/2014)... with a cardiac pacemaker, a low sense of self-competence ... a study in the July Journal of ... of the Society for Developmental and Behavioral Pediatrics ... Williams & Wilkins , a part of Wolters ... protective factor against lower health-related quality of life in ...
Breaking Biology News(10 mins):A start-up at NJIT develops bleeding-control gel for brain surgery 2ACS Infectious Diseases: Unique chemistry journal names editor 2For children with pacemakers, 'self-competence' affects quality of life 2
... The next time you,re outdoors, see if you can spot the ... an easy task trees there are few and far between, ... In the temperate Northeast, dense forests make the exercise a bit ... sequoias often reach higher than the eye can estimate. Knowing ...
... The United States joined more than 50 countries Thursday ... to better track vessels engaged in illegal, unreported and ... highly migratory species. Annual global economic losses due to ... $23 billion. This action is a first step ...
... This release is available in French . ... Neanderthals and is found exclusively in people outside Africa, according ... of the Department of Pediatrics at the University of Montreal ... in the July issue of Molecular Biology and Evolution. ...
Cached Biology News:MIT: The tallest tree in the land 2MIT: The tallest tree in the land 3US joins over 50 nations in adopting recommendation to list vessels engaged in illegal fishing 2US joins over 50 nations in adopting recommendation to list vessels engaged in illegal fishing 3Genetic research confirms that non-Africans are part Neanderthal 2
... All MagCellect Ferrofluid products perform ... with R&D Systems MagCellect Magnet. ... this neodymium iron boron permanent ... x 75 mm test tubes ...
... 2'-O-Methyltransferase converts Cap 0 (or Cap 0-like) ... 1 structure has been shown to increase ... 50%. This improvement is seen in Cap ... Capping System as well as those Cap ...
Request Info...
Form: Ready to use Applications: Western Blot, ELISA...
Biology Products: